Proceedings of the National Academy of Sciences · 2023 · 13 citations · 48 references
Life SciencesMolecular BiologyOncologyCancer GeneticsCancer PharmacologyMolecular OncologyCancer GenomicsCancer ProteomicsCrispr-cas SystemsGene Knockout StrategiesTherapeutic Genome EditingBromodomain InhibitionBromodomain ProteinsCancer Gene EditingCombination TherapyCrispr InterferenceEx Vivo ModelsGenome-wide Crispr ScreeningResistance Mechanism Proteomics
Bromo- and extra-terminal domain inhibitors (BETi) have exhibited therapeutic activities in many cancers. However, the mechanisms controlling BETi response and resistance are not well understood. We conducted genome-wide loss-of-function CRISPR screens using BETi-treated KMT2A-rearranged (KMT2A-r) cell lines. We revealed that Speckle-type POZ protein (SPOP) gene (Speckle Type BTB/POZ Protein) deficiency caused significant BETi resistance, which was further validated in cell lines and xenograft models. Proteomics analysis and a kinase-vulnerability CRISPR screen indicated that cells treated with BETi are sensitive to GSK3 perturbation. Pharmaceutical inhibition of GSK3 reversed the BETi-resistance phenotype. Based on this observation, a combination therapy regimen inhibiting both BET and GSK3 was developed to impede KMT2A-r leukemia progression in patient-derived xenografts in vivo. Our results revealed molecular mechanisms underlying BETi resistance and a promising combination treatment regimen of ABBV-744 and CHIR-98014 by utilizing unique ex vivo and in vivo KMT2A-r PDX models.
48
Selective inhibition of BET bromodomains
P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.3K citations · Full text
Wei Li, Han Xu, Tengfei Xiao et al. · Genome biology · 2014 · 2.8K citations · Full text
Easy quantitative assessment of genome editing by sequence trace decomposition
Eva K. Brinkman, Tao Chen, Mario Amendola et al. · Nucleic Acids Research · 2014 · 2.6K citations · Full text